Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Treprostinil and PK of LY900014 in Healthy Japanese Subjects
NCT02770521Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in diabetes mellitus (DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With One or More Serious Adverse Events at 14 days, Insulin Lispro Maximum Concentration at 420 minutes and 1 more. Started May 2016; status: completed.
02
Drugs
insulin lispro
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02770521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770521.